Read,understand and consent to the blog's disclaimer here before proceeding
Amarin has been in negotiations for a potential transaction (likely an all cash-out acquisition) for a long time. I speculate below are some of the potential suitors.
|Potential Suitor||Product to be replaced/protected||Product sales in US|
|Glaxosmithkline||Lovaza. Patent expires in 2013||Approx $1 billion|
|Abbott||Fibrates||Approx $1 billion|
|Abbott||Niaspan failed to demonstrate improved CV outcomes over statin therapy||Approx $1 billion|
|Pfizer||Several generics entered Lipitor in June 2012 and eroded this franchise||Approx $9b (2011)|
|Astrazeneca||Crestor is still under Patent protection until 2016. A combination product of Vascepa and Crestor could protect this franchise before Crestor's patent expiry.||Approx $5.7b (2011)|
If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.